Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Net Income towards Common Stockholders: 2010-2024

Historic Net Income towards Common Stockholders for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to -$4.7 million.

  • China Pharma Holdings' Net Income towards Common Stockholders rose 41.72% to -$651,482 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 32.76%. This contributed to the annual value of -$4.7 million for FY2024, which is 53.84% down from last year.
  • As of FY2024, China Pharma Holdings' Net Income towards Common Stockholders stood at -$4.7 million, which was down 53.84% from -$3.1 million recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Net Income towards Common Stockholders registered a high of -$2.9 million during FY2020, and its lowest value of -$4.7 million during FY2024.
  • For the 3-year period, China Pharma Holdings' Net Income towards Common Stockholders averaged around -$3.9 million, with its median value being -$4.0 million (2022).
  • Per our database at Business Quant, China Pharma Holdings' Net Income towards Common Stockholders surged by 86.15% in 2020 and then plummeted by 53.84% in 2024.
  • China Pharma Holdings' Net Income towards Common Stockholders (Yearly) stood at -$2.9 million in 2020, then fell by 18.58% to -$3.4 million in 2021, then declined by 16.87% to -$4.0 million in 2022, then climbed by 22.50% to -$3.1 million in 2023, then tumbled by 53.84% to -$4.7 million in 2024.